Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C28698
http://purl.obolibrary.org/obo/NCIT_C28698
|
|---|---|
| Preferred Name | Laniquidar |
| Definitions |
A stereoisomer of verapamil and third-generation P-glycoprotein inhibitor. Laniquidar inhibits the drug efflux pump P-glycoprotein, resulting in higher concentrations of antineoplastic agents in tumor cells that are multi-drug resistant due to the overexpression of P-glycoprotein. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A stereoisomer of verapamil and third-generation P-glycoprotein inhibitor. Laniquidar inhibits the drug efflux pump P-glycoprotein, resulting in higher concentrations of antineoplastic agents in tumor cells that are multi-drug resistant due to the overexpression of P-glycoprotein. (NCI04) |
|---|---|
| prefLabel | Laniquidar
|
| label | Laniquidar
|
| PDQ_Closed_Trial_Search_ID | 38526
|
| code | C28698
|
| prefixIRI | NCIT:C28698
|
| in_subset | |
| Preferred_Name | Laniquidar
|
| FDA_UNII_Code | K3FRN4DDOY
|
| Contributing_Source | FDA
|
| Chemical_Formula | C37H36N4O3
|
| Maps_To | Laniquidar
|
| CAS_Registry | 197509-46-9
|
| NCI_Drug_Dictionary_ID | 38526
|
| Legacy Concept Name | Laniquidar
|
| type | |
| ALT_DEFINITION | A substance that is being studied for its ability to make cancer cells respond to drugs to which they have become resistant. It belongs to the family of drugs called multidrug resistance inhibitors.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38526
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0916124
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |